A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Trial Profile

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LEADER
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 02 Aug 2018 Results of a post-hoc analysis assessing assessing the impact of liraglutide versus placebo in people with type 2 diabetes and at high risk of cardiovascular events on the incidence of DFUs, published in the Diabetes Care
    • 26 Jun 2018 Results from LEADER, SUSTAIN-6 and EXSCEL studies presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2018 Results of post-hoc subgroup analysis assessing cardiovascular outcomes by baseline insulin use: no insulin vs. basal-only vs. other presented at the 78th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top